Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pixium Vision
Keeping the patient at the center is just as important in the development of high-risk innovations that serve unmet needs as it is for all other medtech solutions. That is the view of Pixium Vision CEO Khalid Ishaque, whose company is on the cusp of taking many dry-AMD sufferers out of blindness with artificial bionic vision technology. It recently performed the first successful human implantation and activation of its Prima implant.
Australia's Bionic Vision Technologies (BVT) has raised AUS$23m ($18m) from Hong Kong-based investors, China Huarong International Holdings Ltd and State Path Capital Limited, to develop and commercialize its retinal implant device. The technology could reach the market 3-5 years from now.
Medtech Insight’s new Approvals Tracker recorded 18 approvals outside the US, including five in vitro diagnostic approvals and five cardiovascular device approvals.
The neuromodulation market is growing at a rapid pace and investors and strategics are paying close attention to early-stage innovators. We highlight Cardionomic, Nuviant and Pixium, three young companies that are listening to the brain, fixing broken hearts and making the blind see.
- Digital Health
- Diagnostic Imaging Equipment & Supplies
- Implantable Devices
- Surgical Equipment & Devices
Diagnostic Imaging Equipment & Supplies
- Digital Imaging